After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, including phased data submission to support earlier ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Detroit allowed the E.V. pioneer Tesla to become the most valuable auto company in the world. But then the auto industry’s ...

Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...

SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.

The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a ​rare form of blood ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.